Novel Peptoid Compounds that bind to ACE2 receptor and prevent SARS-CoV-2 (COVID-19) virus entry into human cells
In the race to solve the COVID-19 pandemic crisis, various types of vaccines are in development. Due to the unpredictable nature of the coronavirus, these vaccines may or may not provide long term protection. This technology provides for novel peptoid compounds that could supplement vaccines. Like wearing a face mask to prevent an infection, the peptoid compound act as a “molecular mask” thatprevent virus entry at the human cell level. The synthetic peptoid compounds disrupts spike protein-S and ACE2 interaction and blocks the pseudo virus carrying SARS-Cov-2 protein into human cells. Due to their peptoid-based structures, the compounds provide higher stability, better permeability, and higher shelf-life when compared to current anti-viral drugs such as small molecules, peptides and antibodies. The compounds are also highly biologically amenable, not affecting normal enzymatic function of human ACE2 and not triggering unnecessary immune responses. The peptoid compounds can be effectively and economically administered to subjects through numerous routes, such as nasal administration, ocular administration, and oral administration.
  • Prevention medicine for COVID-19 and other types of coronavirus
  • Developed as a nasal spray, eye drop, or mouthwash to prevent virus entry
  • Developed as a drug to stop the propagation of the virus from cell-to-cell inside the body
Problems Addressed
  • Vaccines may not offer long term protection
  • No ACE2 targeted drug has been developed so far
  • Most of the COVID-19 drug discovery efforts are focused on vaccine development and not preventive medicine
Competitive Advantages
  • Serves as an effective approach for both prevention and treatment
  • Blocks the virus with minimal side effects, without affecting the normal function of the ACE2 enzyme
  • Easier and more economical to develop as compared to current clinically applied drug classes such as small molecules, peptides and antibodies
  • US 63/053,032
Case ID
Gomika Udugamasooriya
Associate Professor, Department of Pharmacological and Pharmaceutical Sciences